会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • CRYSTALLINE FORMS OF SITAGLIPTIN PHOSPHATE
    • 磷酸西他汀的结晶形式
    • WO2009120746A3
    • 2010-01-14
    • PCT/US2009038187
    • 2009-03-25
    • TEVA PHARMATEVA PHARMAPERLMAN NURITRAMATY REVITALABRAMOV MILIFINKELSTEIN NINALANCRY ELIASIS SHAYMITTELMAN ARIEL
    • PERLMAN NURITRAMATY REVITALABRAMOV MILIFINKELSTEIN NINALANCRY ELIASIS SHAYMITTELMAN ARIEL
    • C07D487/04
    • C07D487/04
    • A Sitagliptin phosphate characterized by data selected from the group consisting of: a powder XRD pattern with peaks at 4.7, 13.5, 17.7, 18.3, and 23.7 ±0.2 degrees two theta; a powder XRD pattern with peaks at about 4.7, 13.5, and 15.5 ±0.2 degrees two theta and at least another two peaks selected from the following list: 14.0, 14.4, 18.3, 19.2, 19.5 and 23.7 ±0.2 degrees two theta; and a powder XRD pattern with peaks at about 13.5, 19.2, and 19.5 ±0.2 degrees two theta and at least another two peaks selected from the following list: 4.7, 14.0, 15.1, 15.5, 18.3, and 18.7 ±0.2 degrees two theta; a powder XRD pattern with peaks at about 13.5, 15.5, 19.2, 23.7, and 24.4 ±0.2 degrees two theta; and a powder XRD pattern with peaks at about 4.65, 13.46, 17.63, 18.30, and 23.66 ±0.10 degrees two theta, processes for preparing said Sitagliptin crystalline form, and pharmaceutical compositions thereof, are provided.
    • 磷酸西他列汀,其特征在于选自以下的数据:粉末XRD图谱,其峰为4.7,13.5,17.7,18.3和23.7±0.2度2θ; 在约4.7,13.5和15.5±0.2度2θ处具有峰的粉末XRD图案和至少另外两个选自以下列表的峰:14.0,14.4,18.3,19.2,19.5和23.7±0.2度2θ; 和具有在约13.5,19.2和19.5±0.2度2θ处以及从下列列表中选择的至少另外两个峰的峰的粉末XRD图:4.7,14.0,15.1,15.5,18.3和18.7±0.2度2θ; 在约13.5,15.5,19.2,23.7和24.4±0.2度2θ处具有峰的粉末XRD图案; 并且提供了在约4.65,13.46,17.63,18.30和23.66±0.10度2θ处具有峰的粉末XRD图案,制备所述西格列汀结晶形式的方法及其药物组合物。